Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.
Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P, Li X, Gumin J, Zheng H, Hu L, Yli-Harja O, Haapasalo H, Visakorpi T, Liu X, Liu CG, Sawaya R, Fuller GN, Chen K, Lang FF, Nykter M, Zhang W. Parker BC, et al. Among authors: visakorpi t. J Clin Invest. 2013 Feb;123(2):855-65. doi: 10.1172/JCI67144. Epub 2013 Jan 9. J Clin Invest. 2013. PMID: 23298836 Free PMC article.
Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.
Augello MA, Burd CJ, Birbe R, McNair C, Ertel A, Magee MS, Frigo DE, Wilder-Romans K, Shilkrut M, Han S, Jernigan DL, Dean JL, Fatatis A, McDonnell DP, Visakorpi T, Feng FY, Knudsen KE. Augello MA, et al. Among authors: visakorpi t. J Clin Invest. 2013 Jan;123(1):493-508. doi: 10.1172/JCI64750. Epub 2012 Dec 21. J Clin Invest. 2013. PMID: 23257359 Free PMC article.
Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
Leinonen KA, Saramäki OR, Furusato B, Kimura T, Takahashi H, Egawa S, Suzuki H, Keiger K, Ho Hahm S, Isaacs WB, Tolonen TT, Stenman UH, Tammela TL, Nykter M, Bova GS, Visakorpi T. Leinonen KA, et al. Among authors: visakorpi t. Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2333-44. doi: 10.1158/1055-9965.EPI-13-0333-T. Epub 2013 Oct 1. Cancer Epidemiol Biomarkers Prev. 2013. PMID: 24083995 Free PMC article.
A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding.
Huang Q, Whitington T, Gao P, Lindberg JF, Yang Y, Sun J, Väisänen MR, Szulkin R, Annala M, Yan J, Egevad LA, Zhang K, Lin R, Jolma A, Nykter M, Manninen A, Wiklund F, Vaarala MH, Visakorpi T, Xu J, Taipale J, Wei GH. Huang Q, et al. Among authors: visakorpi t. Nat Genet. 2014 Feb;46(2):126-35. doi: 10.1038/ng.2862. Epub 2014 Jan 5. Nat Genet. 2014. PMID: 24390282
DOT1L-HES6 fusion drives androgen independent growth in prostate cancer.
Annala M, Kivinummi K, Leinonen K, Tuominen J, Zhang W, Visakorpi T, Nykter M. Annala M, et al. Among authors: visakorpi t. EMBO Mol Med. 2014 Sep;6(9):1121-3. doi: 10.15252/emmm.201404210. EMBO Mol Med. 2014. PMID: 25006183 Free PMC article. No abstract available.
Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer.
Annala M, Kivinummi K, Tuominen J, Karakurt S, Granberg K, Latonen L, Ylipää A, Sjöblom L, Ruusuvuori P, Saramäki O, Kaukoniemi KM, Yli-Harja O, Vessella RL, Tammela TL, Zhang W, Visakorpi T, Nykter M. Annala M, et al. Among authors: visakorpi t. Oncotarget. 2015 Mar 20;6(8):6235-50. doi: 10.18632/oncotarget.3359. Oncotarget. 2015. PMID: 25749039 Free PMC article.
The evolutionary history of lethal metastatic prostate cancer.
Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio HML, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC; ICGC Prostate Group; Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS. Gundem G, et al. Among authors: visakorpi t. Nature. 2015 Apr 16;520(7547):353-357. doi: 10.1038/nature14347. Epub 2015 Apr 1. Nature. 2015. PMID: 25830880 Free PMC article.
Epigenetically altered miR-193b targets cyclin D1 in prostate cancer.
Kaukoniemi KM, Rauhala HE, Scaravilli M, Latonen L, Annala M, Vessella RL, Nykter M, Tammela TL, Visakorpi T. Kaukoniemi KM, et al. Among authors: visakorpi t. Cancer Med. 2015 Sep;4(9):1417-25. doi: 10.1002/cam4.486. Epub 2015 Jul 1. Cancer Med. 2015. PMID: 26129688 Free PMC article.
293 results